Tutt AL - Search Results

1

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T. Stockmeyer B, et al. Among authors: tutt al. J Immunol. 2000 Nov 15;165(10):5954-61. doi: 10.4049/jimmunol.165.10.5954. J Immunol. 2000. PMID: 11067958

2

Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.

Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, van Ojik HH, Dechant M, Valerius T, Keler T, Tutt AL, Glennie MJ, van Royen EA, Capel PJ, van de Winkel JG. Heijnen IA, et al. Among authors: tutt al. J Immunol. 1997 Dec 1;159(11):5629-39. J Immunol. 1997. PMID: 9548506

3

Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

Würflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M, Gramatzki M. Würflein D, et al. Among authors: tutt al. Cancer Res. 1998 Jul 15;58(14):3051-8. Cancer Res. 1998. PMID: 9679970

4

Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody.

Tutt AL, Reid R, Wilkins BS, Glennie MJ. Tutt AL, et al. J Immunol. 1995 Sep 15;155(6):2960-71. J Immunol. 1995. PMID: 7673714

5

Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.

Tutt AL, French RR, Illidge TM, Honeychurch J, McBride HM, Penfold CA, Fearon DT, Parkhouse RM, Klaus GG, Glennie MJ. Tutt AL, et al. J Immunol. 1998 Sep 15;161(6):3176-85. J Immunol. 1998. PMID: 9743386

6

Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma.

Honeychurch J, Tutt AL, Valerius T, Heijnen IA, Van De Winkel JG, Glennie MJ. Honeychurch J, et al. Among authors: tutt al. Blood. 2000 Nov 15;96(10):3544-52. Blood. 2000. PMID: 11071653 Free article.

7

Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.

Tutt A, Stevenson GT, Glennie MJ. Tutt A, et al. J Immunol. 1991 Jul 1;147(1):60-9. J Immunol. 1991. PMID: 1675655

8

Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.

Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS. Ellis JH, et al. J Immunol. 1995 Jul 15;155(2):925-37. J Immunol. 1995. PMID: 7608568

9

T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.

Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. Tutt AL, et al. J Immunol. 2002 Mar 15;168(6):2720-8. doi: 10.4049/jimmunol.168.6.2720. J Immunol. 2002. PMID: 11884438

10

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ. Williams EL, et al. Among authors: tutt al. J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11. J Immunol. 2013. PMID: 24026082

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters